Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 20,815 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Completed Phase 2 Interventional

OGX-427 in Castration Resistant Prostate Cancer Patients

NCT01120470
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
OGX-427, Prednisone
Drug
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 3, 2026, 6:49 PM EDT
Withdrawn Not applicable Interventional

Strength for Health

NCT01882972
View directory record Official record
Conditions
Colon Cancer
Interventions
Exercise, Meditation
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 3, 2026, 6:49 PM EDT
Active, not recruiting Not applicable Interventional

Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

NCT01943695
View directory record Official record
Conditions
Breast Cancer
Interventions
Aerobic Training, Educational Information, Supervised Home Based Training
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Terminated Phase 1 Interventional

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT05961839
View directory record Official record
Conditions
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Interventions
SGR-2921
Drug
Lead sponsor
Schrödinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Denver, Colorado • Fairway, Kansas • Buffalo, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 3, 2026, 6:49 PM EDT
Recruiting Early Phase 1 Interventional

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

NCT05553782
View directory record Official record
Conditions
Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer
Interventions
Implantable Microdevice (IMD)
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Active, not recruiting Phase 2 Interventional

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

NCT04699123
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
NC318 800 mg, NC318 400 mg, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Active, not recruiting Phase 4 Interventional

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

NCT06803888
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions
Interventions
Bariatric Surgery, Semaglutide, Tirzepatide
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Not listed Not applicable Interventional

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

NCT01017627
View directory record Official record
Conditions
Anemia, Mortality
Interventions
Early anemia diagnosis and treatment, No change from normal routine
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 3, 2026, 6:49 PM EDT
Not listed Not applicable Interventional

Pain SMART: Shared Medical Appointments to Refocus Treatment

NCT03707886
View directory record Official record
Conditions
Chronic Pain
Interventions
Pain SMART, minimally enhanced usual care
Behavioral · Other
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Results available

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

NCT03083873
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
LN-145, LN-145-S1
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 3, 2026, 6:49 PM EDT
Not listed Not applicable Interventional

Superficial Dry Needling for Cervicogenic Headache

NCT05444296
View directory record Official record
Conditions
Headache
Interventions
Superficial Dry Needling, Non-thrust Mobilizations only
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 3, 2026, 6:49 PM EDT
Completed No phase listed Observational

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
Interventions
Blood-based cell-free cfDNA qPCR assay
Diagnostic Test
Lead sponsor
Cadex Genomics
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
Little Rock, Arkansas • Sunnyvale, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 3, 2026, 6:49 PM EDT
Active, not recruiting Not applicable Interventional

Program for Fully Understanding Eating and Lifestyle Change (FUEL)

NCT05562427
View directory record Official record
Conditions
Obesity
Interventions
Gold-Standard Online Behavioral Obesity Treatment
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Results available

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03005327
View directory record Official record
Conditions
WHIM Syndrome
Interventions
X4P-001
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Not applicable Interventional

Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - St. Joseph Mercy Oakland

NCT01825954
View directory record Official record
Conditions
Fibromyalgia
Interventions
RINCE
Device
Lead sponsor
Cerephex Corporation
Industry
Eligibility
22 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Oct 3, 2026, 6:49 PM EDT
Not yet recruiting Not applicable Interventional

Hospital-Onset Sepsis Systematic Detection and Structured Interventions

NCT07804251
View directory record Official record
Conditions
Sepsis, Deterioration, Clinical, Critical Illness, Early Warning Score
Interventions
Algorithm-triggered sepsis alert with structured critical care team activation
Other
Lead sponsor
Patricks Lyons
Other
Eligibility
18 Years and older
Enrollment
3,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring the Impact of MANNA s Medically Tailored Meal Program in Patients With a Non-terminal Cancer Diagnosis

NCT05118802
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Interview, Survey Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 3, 2026, 6:49 PM EDT
Recruiting Not applicable Interventional

A Multi-Site Feasibility Trial of Embedded Emergency Department Physical Therapy

NCT07224945
View directory record Official record
Conditions
Low Back Pain
Interventions
Embedded Emergency Department Physical Therapy, Usual Care
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

NCT03350672
View directory record Official record
Conditions
Hiv
Interventions
FTC/TAF
Drug
Lead sponsor
Philadelphia Fight
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

NCT00003972
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, sargramostim, busulfan, carboplatin, cyclophosphamide, melphalan, paclitaxel, tamoxifen citrate, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

NCT00366145
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Standard of Care for GVHD
Biological · Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
6 Months to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 3, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00248495
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, pemetrexed disodium, adjuvant therapy, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 3, 2026, 6:49 PM EDT